Working… Menu

Liraglutide in Spinal Fluid (LIRA-CSV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02104037
Recruitment Status : Completed
First Posted : April 4, 2014
Last Update Posted : April 4, 2014
Information provided by (Responsible Party):
Mikkel Christensen, University Hospital, Gentofte, Copenhagen

Brief Summary:
The purpose of this study is to investigate transfer of liraglutide from blood to cerebrospinal fluid.

Condition or disease Intervention/treatment Phase
Liraglutide Blood-brain Transfer Procedure: Lumbar puncture Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Liraglutide in Spinal Fluid
Study Start Date : January 2012
Actual Primary Completion Date : December 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Liraglutide

Arm Intervention/treatment
Experimental: Liraglutide treated patients Procedure: Lumbar puncture

Primary Outcome Measures :
  1. cerebrospinal fluid concentration of liraglutide [ Time Frame: time 60 minutes ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Type 2 diabetes treated with liraglutide 1.8 mg for 1 month and 5% weight loss

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02104037

Layout table for location information
Diabetes Research Division, Department of Medicine
Hellerup, Denmark, 2900
Sponsors and Collaborators
Mikkel Christensen

Layout table for additonal information
Responsible Party: Mikkel Christensen, Dr., University Hospital, Gentofte, Copenhagen Identifier: NCT02104037     History of Changes
Other Study ID Numbers: H-2-2011-027
First Posted: April 4, 2014    Key Record Dates
Last Update Posted: April 4, 2014
Last Verified: April 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypoglycemic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists